Adtran’s Oscilloquartz high-performance optical cesium technology integrated in Swiss timescale infrastructure at METAS
4.11.2024 10:00:00 CET | Business Wire | Press Release
Adtrantoday announced that Switzerland’s Federal Institute of Metrology METAS has successfully deployed its OSA 3300 HP, improving national timekeeping performance and supporting critical scientific research. As the industry’s first high-performance optical cesium atomic clock, the OSA 3300 HP sets new standards for accuracy and stability, while assuring 10 years of operation. It also strengthens Switzerland’s contribution to Universal Time Coordinated (UTC), bolstering its position in the global timekeeping network. By providing an ultra-stable frequency source, the OSA 3300 HP offers major advances in the field of metrology, ensuring that Switzerland remains at the forefront of precision measurement and timekeeping.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241101122191/en/
Adtran’s OSA 3300 HP is helping METAS deliver ultra-precise and reliable timekeeping. (Photo: Business Wire)
“The addition of the OSA 3300 HP to our metrological infrastructure is a significant step forward in our quest to provide the most precise and reliable timekeeping possible. The solution supports our contribution to BIPM and aligns perfectly with our mission to advance the science of measurement and maintain the highest standards of accuracy. By harnessing Adtran’s Oscilloquartz technology, we’re also cementing Switzerland’s position in the international timekeeping community,” said Jacques Morel, head of the laboratory photonics, time and frequency at METAS. “Achieving this milestone required close collaboration with the Oscilloquartz team. Their prompt delivery – completing the delivery within just two months from the purchase order – along with their expertise enabled a seamless integration, allowing us to uphold our commitment to the highest standards of efficiency and reliability without interruption.”
As the world’s first commercial optical cesium atomic clock, the OSA 3300 HP provides unmatched timing accuracy and long-term stability, offering a 10-year lifespan compared to the five-year performance of traditional magnetic deflection high-performance atomic clocks. Its advanced optical pumping technology ensures a stable frequency source, delivering nanosecond precision over an extended lifespan and significantly surpassing magnetic alternatives. This strengthens METAS’s ability to maintain Switzerland’s national measurement standards for time and frequency and to contribute to UTC. With its compact design, intuitive controls and remote SNMP management capabilities, the OSA 3300 HP integrates seamlessly into METAS’s time laboratory infrastructure, ensuring the integrity of its timekeeping operations and solidifying its status as a global leader in precision measurement and synchronization standards.
“METAS is at the forefront of precision measurement and timekeeping, setting global benchmarks for metrology standards. We’re proud to partner closely with them, making our industry-first high-performance optical cesium product a direct contributor to their UTC system and enhancing the accuracy and stability of global time synchronization,” commented Stuart Broome, GM of EMEA sales at Adtran. “The OSA 3300 HP, with its advanced optical pumping technology, delivers unparalleled timing precision and long-term reliability, significantly outperforming traditional high-performance magnetic deflection cesium clocks. Delivering the solution to METAS within an exceptionally short timeframe of less than two months also highlights our unwavering commitment to efficiency and reliability. Now a vital part of METAS’s infrastructure, this innovative technology provides a stable, ultra-precise frequency source that uniquely meets the stringent demands of scientific research and industrial applications worldwide.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101122191/en/
Contacts
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Rhonda Lambert
+1 256 963 7450
investor.relations@adtran.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom